ObsEva SA to Participate in JP Morgan Virtual Healthcare Conference January 11 - 14, 2021
ObsEva SA (NASDAQ: OBSV) has announced its participation in the JP Morgan Virtual Healthcare Conference scheduled from January 11-14, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ObsEva SA (NASDAQ: OBSV) has announced its participation in the JP Morgan Virtual Healthcare Conference scheduled from January 11-14, 2021. The company will present on January 14, 2021, at 7:30 a.m. ET. The webcast of the presentation will be accessible on ObsEva's website under the 'Investors' section. ObsEva focuses on developing therapies for women’s reproductive health, with a late-stage pipeline addressing conditions like endometriosis and preterm labor. For more details, visit www.ObsEva.com.
Details
News Market Reaction – OBSV
The recorded move for OBSV in the trading session of this news was -1.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Geneva, Switzerland and Boston, MA – January 7, 2021 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will be participating in the JP Morgan Virtual Healthcare Conference taking place January 11-14, 2021. ObsEva will present on Thursday, January 14, 2021 at 7:30 a.m. Eastern Time (ET).
The presentation webcast will be available in the “Investors” section of ObsEva’s website www.ObsEva.com.
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
For further information, please contact:
CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.